Exact Sciences Highlights the Impact of Oncotype DX® and Genomic Insights at SABCS 2024
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, will present a robust array of new data at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13. With 10 abstracts, the company aims to underscore the transformative role of its Precision Oncology portfolio in advancing breast cancer care.
Enhancing Treatment Decisions with Oncotype DX®
New findings reinforce the value of the Oncotype DX Breast Recurrence Score® test, showcasing its ability to guide treatment decisions, improve outcomes, and optimize healthcare costs worldwide. According to Dr. Rick Baehner, Chief Medical Officer of Precision Oncology at Exact Sciences, “The Oncotype DX test has been a trusted resource for personalized treatment planning over the last 20 years, empowering clinicians and patients alike. Our presence at SABCS further solidifies our commitment to improving outcomes across all stages of cancer care.”
The test’s ability to predict chemotherapy benefits and recurrence risk is particularly significant in diverse populations. For example, a retrospective analysis highlighted higher recurrence scores in African American women compared to non-Hispanic White women, with comparable survival outcomes. This underscores the importance of equitable care and continued research to address racial disparities.
New Data Presentations
At SABCS 2024, Exact Sciences will present findings from global collaborations with leading breast cancer experts. The data includes insights on cost-effectiveness, genomic profiling, and the predictive power of the Oncotype DX test in diverse patient groups.
Featured Presentations
- Adjuvant Chemotherapy in HR+/HER2- Breast Cancer
- Session: Late-breaking oral presentation (GS3-04)
- Date/Time: December 13, 9:00-11:45 AM CST
- Final survival results from the WSG ADAPT-HR+/HER2- trial will demonstrate the impact of genomic profiling on survival outcomes.
- Oncotype DX and Cost-Effectiveness in Japan
- Session: Poster P4-11-07
- Date/Time: December 12, 5:30-7:00 PM CST
- A cost-effectiveness analysis highlights how the test aids treatment decisions and optimizes healthcare resources in Japan.
- Pregnancy and Breast Cancer Outcomes
- Session: Poster P1-03-30
- Date/Time: December 11, 12:30-2:00 PM CST
- A genomic risk score analysis explores outcomes for patients diagnosed during pregnancy.
- Genomic Insights by Race and Ethnicity
- Session: Poster P2-07-06
- Date/Time: December 11, 5:30-7:00 PM CST
- This study analyzes how recurrence scores correlate with outcomes across racial groups, emphasizing equity in cancer care.
- Molecular Pathways and Targeted Therapies
- Session: Poster P4-03-25
- Date/Time: December 12, 5:30-7:00 PM CST
- Insights into actionable genetic alterations affecting PI3K/AKT and MAPK pathways in breast cancer are presented.
Expanding the Precision Oncology Portfolio
Exact Sciences is also highlighting advancements beyond Oncotype DX. The OncoExTra® test, a comprehensive tumor profiling solution, uses whole exome and transcriptome sequencing to support therapy selection for advanced cancers. By analyzing approximately 20,000 genes, OncoExTra provides one of the most detailed views of genomic and transcriptomic alterations available today.
Additionally, the Riskguard® hereditary cancer test evaluates risks for 10 common cancers using a simple blood or saliva sample, empowering patients and providers to make proactive care decisions.
Commitment to Global Cancer Care
The new findings presented at SABCS illustrate Exact Sciences’ dedication to addressing unmet needs in breast cancer treatment through advanced diagnostics. By integrating cutting-edge genomic technologies, the company strives to provide personalized solutions that improve patient outcomes while promoting equity in care delivery.
For 20 years, Exact Sciences has been at the forefront of cancer innovation, shaping the future of oncology diagnostics. With its Precision Oncology portfolio, the company continues to bridge the gap between research and clinical application, ensuring patients worldwide receive the most effective care possible.
For more details, visit precisiononcology.exactsciences.com.
